Yazar "Bozkurt, Oktay" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Birinci basamakta hedefe yönelik ajanlarla tedavi edilen RAS mutasyonu taşımayan metastatik kolorektal kanser hastalarında gerçek yaşam verileri: Ulusal onco-colon Türkiye kayıt sistemi
    (2026) Bilir, Cemil; Özçelik, Melike; Bozkurt, Oktay; Çiçin, Irfan; Sakin, Abdullah; Geredeli, Caglayan; Yalcin, Suayib
    Amaç: Anti-EGFR ajanlarının etkinliği metastatik kolorektal kanserde (mKRK) gösterilmiştir. Gerçek yaşam verileri, klinik çalışmaların dışında kalan hastalara ait bulguları ortaya koymak açısından özellikle önemlidir. Bu nedenle, RAS vahşi tip mKRK’li hastalarda gerçek yaşam verilerini araştırmayı amaçladık. Yöntemler: Ocak 2016 ile Nisan 2019 tarihleri arasında mKRK tanısı alan hastalara ait tıbbi kayıtlar 28 merkezden toplandı. Hastalar, birinci basamak biyolojik tedavilere göre anti-EGFR grubu (Grup A (panitumumab) ve B (setuksimab)) ve anti- VEGF grubu (Grup C) olarak karşılaştırıldı. Bulgular: Belgelenmiş RAS vahşi tip mKRK’li toplam 1064 hasta değerlendirildi. Bu hastaların sırasıyla %33’ü panitumu- mab, %37’si setuksimab ve %30’u birinci basamakta anti-VEGF içeren rejimlerle tedavi edildi. Genel yanıt oranı Grup A, B ve C’de sırasıyla %46,4, %41,9 ve %41,5 idi (p = 0,170). Medyan genel sağkalım (OS) Grup A, B ve C’de sırasıyla 26, 27 ve 23 ay olarak bulundu (p = 0,044). Panitumumab, setuksimab ve bevacizumab alan hastaların medyan progresyonsuz sağka- lımı (PFS) sırasıyla 11,6, 11,0 ve 9,6 ay idi (p = 0,012). Çok değişkenli analizde, performans durumu (PS) 0-1 ve BRAF vahşi tip durumu OS için bağımsız prognostik faktörler olarak; yalnızca BRAF vahşi tip durumu ise PFS için bağımsız prognostik faktör olarak bulundu (p<0,05). Sonuç: Bu gerçek yaşam verilerinin analizi, RAS vahşi tip mKRK’de anti-EGFR ajanlarının karşılaştırılabilir etkinliğini doğ- rulamaktadır. Ancak, bu hastalarda anti-EGFR tedavisi, anti-VEGF tedavisine kıyasla PFS ve OS avantajı sağlamaktadır. Ayrıca, BRAF vahşi tip tümörlere sahip hastalarda PFS ve OS daha iyi bulunmuştur.
  • Küçük Resim
    Öğe
    The impact of systemic inflammatory markers on survival in metastatic gastric cancer patients receiving first-line chemotherapy
    (2019) Bozkurt, Oktay; Firat, Sedat Tarik; Dogan, Ender; Cosar, Ramazan; Inanc, Mevlude; Ozkan, Metin
    ABSTRACT Aim: The prognostic impact of elevated systemic inflammatory tools, including the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR), remains moot in cancer patients. This research was performed to explore the predictive worth of these markers for prognoses in metastatic gastric cancer (mGC) patients receiving chemotherapy.Material and Methods: We retrospectively appraised 158 patients diagnosed with mGC between February 2009 and November 2017. According to threshold values that were identified by receiver operating characteristic (ROC) curve analysis, the NLR and PLR were each divided into two groups: ≤ 2.11 and >2.11, ≤ 158.8, and >158.8, respectively. The Cox proportional hazards model was applied to uncover the probable predictors of progression-free survival (PFS) and overall survival (OS).Results: According to univariate analysis, poor performance status, high NLR, high PLR, and anemia were significantly correlated with inferior OS receiving first-line palliative chemotherapy. High NLR, high PLR, and anemia were significantly correlated with poor PFS. In the multiple analysis, an elevated NLR was identified to be an independent predictor of inferior OS (OR: 2.70, 95% CI: 1.75-4.16, p0.001) and PFS (OR: 1.47, 95% CI: 1.00-2.17, p=0.047). Additionally, anemia was independent prognostic factors for the OS (OR: 0.69, 95% CI: 0.47-0.99, p=0.046).Conclusion: Findings of this research revealed that NLR was an independent prognostic tool of PFS and OS in mGC patients undergoing first-line chemotherapy.Keywords: Metastatic gastric cancer; neutrophil to lymphocyte ratio; platelet-to-lymphocyte ratio; prognosis.
  • Küçük Resim
    Öğe
    Risk factors for 30-day mortality in patients with cancer and COVID-19 in Turkey: A single center retrospective study
    (2022) Mutlu, Emel; Firat, Sedat Tarik; Inanc, Mevlude; Bozkurt, Oktay; Cosar, Ramazan; Ozkan, Metin
    Aim: We aimed to investigate the factors affecting mortality in cancer patients with COVID-19. Materials and Methods: 120 cancer patients followed-up in Erciyes University Medical Oncology Department were included in the study. Patients with a diagnosed cancer over the age of 18 years and diagnosis of COVID-19 between April 1 and December 1 2020 were participated in the study. The relationship between clinical, demographic, laboratory values and 30-day mortality were evaluated using the Chi-square and Fisher's exact test. Risk factors for mortality were identified by univariable and multivariable logistic regression models. Results: 120 cancer patients were accepted in the study and 30 (25%) had died within 30 days after COVID-19 positivity. Hospitalization rate of cancer patients with COVID-19 was 67.5% and 23 (19.2%) of patients were admitted to intensive care unit (ICU). 34.6% of hospitalized patients and 95.7% of those admitted in the ICU died within 30 days. In multivariable logistic regression analysis, it was concluded that the presence of lymphopenia (OR 2.2, 95% CI 1.54-13.6, p = 0.04), high neutrophil-lymphocyte ratio (NLR) (OR 3.1, 95% CI 1.21-9.8, p = 0.02), dyspnea (OR 2.5 95% CI 0.32-11.2, p = 0.04), lung cancer diagnoses (OR 3.3 95% CI 1.54-9.7, p = 0.03), male gender (OR 2.17 95% CI 1.1-7.3, p = 0.03) ) were determined that increased 30-day mortality. Conclusion: High incidence of cancer and the risk of immunosuppression in these patients increased the importance of COVID-19. Cancer patients with COVID-19 need to be treated more carefully because they are vulnerable to infection and can be mortal.